Clinical Trial Protocol Development: Key Components and Best Practices

A clinical trial protocol is the operational and scientific document that defines how a study will be conducted, what data will be collected, and how participant safety will be protected. For students, researchers, and life-science professionals preparing to write a protocol, the essential components include a clear statement of objectives, a detailed study design, explicit eligibility criteria, a statistical analysis plan, and robust safety monitoring procedures. The SPIRIT 2025 statement, an updated international guideline for randomized trial protocols, identifies the minimum items that should appear in a protocol and emphasizes that the protocol serves as the foundation for study planning, conduct, reporting, and external review (SPIRIT 2025 Statement). This article provides a practical framework for protocol development, a template outline, and common pitfalls to avoid.

At a Glance

The table below summarizes the core protocol sections, their primary purpose, and the key questions each section must answer.

The Role of the Protocol in Clinical Research

The protocol is not a formality. It is the document that investigators, sponsors, ethics committees, and regulators use to evaluate whether a study is scientifically sound and ethically acceptable. The SPIRIT 2025 update added new items to the checklist, including an open-science section and a requirement to describe how patients and the public will be involved in trial design, conduct, and reporting (SPIRIT 2025 Statement). This reflects a broader shift toward transparency and participant engagement in clinical research.

A well-written protocol also reduces the risk of protocol deviations. A retrospective analysis of 14 clinical trials with 202 enrolled subjects found that longer study participation was associated with an increased number of protocol deviations, while no significant associations were found between deviations and demographic factors such as gender or age (Impact of Protocol Amendments on Study Protocol Adherence). This finding suggests that protocol complexity and duration, instead of patient characteristics, drive non-adherence. Clear, concise protocols that minimize unnecessary visits and assessments can reduce the burden on participants and improve data quality.

Core Principles of Protocol Design

Clarity and Precision

Every element of a protocol must be described with enough detail that another research team could replicate the study. The EFICAN trial protocol, which evaluated a 12-week resistance and aerobic exercise program in breast cancer survivors, used a consensus-based exercise reporting template to maximize transparency, replicability, and clinical applicability (EFICAN Study Protocol). This approach ensured that the intervention was described in sufficient detail, including the number of sessions, the duration of each session, and the progression criteria.

Patient-Centered Design

Protocols that are over-complex or imprecise are a main risk for slow enrollment and data variability, which can lead to a failed study (How to Make a Protocol Patient-Centric). Input from patients during protocol development makes the evaluation of required visits and assessments more reliable. The RECOVER Clinical Trials Protocol Working Groups, which designed trials addressing Long COVID, found that patient representatives contributed valuable perspectives on participant burden and lived experience, although gaps in role clarity and feedback integration persisted (Engaging Patients in RECOVER Protocol Development). Structured engagement practices and clear expectations are necessary to ensure meaningful patient participation.

Risk-Based Quality Management

The International Council for Harmonisation Good Clinical Practice E8 guidelines introduced a more patient-centric, risk-based approach to clinical trial quality (Impact of Protocol Amendments on Study Protocol Adherence). This means that protocol development should include an assessment of the risks to participant safety and data integrity, followed by the implementation of mitigation strategies. Key risk indicators, such as protocol amendments and informed consent changes, should be monitored throughout the trial.

Essential Protocol Sections

Background and Rationale

The background section should summarize the existing evidence, explain the scientific gap, and justify the need for the study. For example, the PRIMARY2 trial protocol describes how multiparametric magnetic resonance imaging has an established role in diagnosing clinically significant prostate cancer but notes that the addition of PSMA PET/CT may enable some men to avoid transperineal prostate biopsy without missing clinically significant cancer (PRIMARY2 Trial Protocol). The rationale should be specific and grounded in the literature.

Objectives and Endpoints

The objectives should be stated as clear, measurable questions. The PRIMARY trial, a prospective multicenter cross-sectional study, had primary objectives to determine the additive value of PSMA PET/CT when combined with mpMRI for detecting clinically significant prostate cancer and to determine the proportion of men who could have avoided biopsy with a positive mpMRI but negative PSMA PET/CT (PRIMARY Trial Protocol). Secondary objectives addressed the proportion of men with cancer detected only by PSMA PET/CT or only by systematic biopsy, and whether there may be health economic benefit or harm from incorporating PSMA PET/CT into the diagnostic algorithm.

Endpoints must be defined with precision. The VERITAC-2 study, a Phase III trial comparing vepdegestrant to fulvestrant in ER+/HER2- advanced breast cancer, used progression-free survival by blinded independent central review as the primary endpoint, assessed in the intention-to-treat population and the ESR1 mutation-positive subpopulation (VERITAC-2 Study). Secondary endpoints included overall survival, tumor response, safety, pharmacokinetics, patient-reported outcomes, and circulating tumor DNA biomarkers.

Study Design

The study design section describes the structure of the trial, including randomization, blinding, and control groups. The ProPAC-COVID trial, which evaluated azithromycin and hydroxychloroquine in hospitalized patients with COVID-19, used a multicenter, randomized, placebo-controlled, 2-arm, parallel-group, double-blind design (ProPAC-COVID Protocol). The design section should also describe the allocation ratio, stratification factors, and any adaptive elements.

The Probe-Fluid pilot trial, which compared protocol-based fluid management to usual care in critically ill patients on kidney replacement therapy, used an open-label, multicenter, pilot randomized controlled design (Probe-Fluid Pilot Trial Protocol). The intervention consisted of a prescription template updated at least once daily, specifying a 24-hour fluid balance target and a prescription for fluid removal. The protocol acknowledged that the application of the intervention relied on the clinical judgment of the attending care team, which could affect fidelity.

Eligibility Criteria

Inclusion and exclusion criteria define the study population. The ProPAC-COVID protocol specified inclusion criteria such as admission to Danish emergency departments, age 18 years or older, hospitalization for 48 hours or less, and a positive COVID-19 test (ProPAC-COVID Protocol). Exclusion criteria included known intolerance or allergy to the study drugs, neurogenic hearing loss, psoriasis, retinopathy, maculopathy, visual field changes, breastfeeding, and severe liver disease.

The ILIA study, which evaluated smartphone-based relapse monitoring for patients with schizophrenia or schizoaffective disorder, included patients with ICD-10 F20/F25 diagnoses who were receiving routine psychiatric outpatient treatment (ILIA Study Protocol). The protocol specified that patients in the intervention group would use the app for one year, complete a weekly ten-item Early Warning Signs Questionnaire, and receive in-app feedback.

Statistical Analysis Plan

The statistical analysis plan must specify the sample size, the primary and secondary analyses, and the methods for handling missing data. The PRIMARY2 trial planned to recruit 660 participants and used a 1:1 randomization ratio in permuted blocks stratified by center (PRIMARY2 Trial Protocol). The primary outcome, avoidance of transperineal prostate biopsy, was to be measured at 6 months from randomization.

The EFICAN trial planned to enroll 60 female breast cancer survivors and used peak isometric muscular strength of the lower and upper body as the primary outcome measure, assessed with an electromechanical dynamometer (EFICAN Study Protocol). Secondary outcomes included cardiorespiratory fitness, upper-joint mobility, and disability.

Safety Monitoring

Safety monitoring is a critical component of any protocol. The template protocol for clinical trials investigating vaccines, published in Vaccine, was designed to include safety-relevant information required by regulatory authorities and deemed useful by investigators (Template Protocol for Vaccine Trials). This template may serve phases I through IV clinical trials and supports future site strengthening efforts.

The protocol should describe how adverse events will be collected, classified, and reported, as well as any stopping rules or data safety monitoring board procedures. The SPIRIT 2025 update placed additional emphasis on the assessment of harms and the description of interventions and comparators (SPIRIT 2025 Statement).

Protocol Development Workflow

Step 1: Define the Research Question

The research question should be specific, measurable, and clinically relevant. The PRIMARY trial was designed to determine whether a limited pelvic-only PSMA PET/CT in combination with routine mpMRI could reliably discriminate men with clinically significant prostate cancer from those without (PRIMARY Trial Protocol). A well-defined research question guides all subsequent decisions.

Step 2: Conduct a Literature Review

A thorough literature review identifies the existing evidence and justifies the need for the study. The NCBI Literature Resources and PubMed databases provide access to peer-reviewed publications that can inform the background and rationale sections (NCBI Literature Resources, PubMed). The review should also identify validated outcome measures and established protocols that can be adapted.

Step 3: Draft the Protocol Using a Template

Protocol templates can streamline the development process. The National Institutes of Health and the U.S. Food and Drug Administration released a protocol template for phase 2 and 3 IND/IDE clinical trials, which has been translated into other languages to support international use (Japanese Translation of NIH and FDA Protocol Template). Templates ensure that all required elements are included and reduce the risk of omissions.

Step 4: Engage Stakeholders

Patient and public involvement in protocol development can improve the feasibility and acceptability of the study. The RECOVER experience demonstrated that patient representatives contributed valuable insights into participant burden, but also highlighted the need for structured engagement practices and clear expectations (Engaging Patients in RECOVER Protocol Development). Researchers and project leaders noted the value of inclusive perspectives in trial design.

Step 5: Review and Revise

The protocol should be reviewed by all members of the research team, including statisticians, clinicians, and research coordinators. The review should assess the clarity of the language, the feasibility of the procedures, and the adequacy of the safety monitoring plan. The SPIRIT 2025 checklist can be used as a tool to ensure that all minimum items are addressed (SPIRIT 2025 Statement).

Step 6: Submit for Ethics and Regulatory Approval

The final protocol is submitted to the institutional review board or independent ethics committee, and to the relevant regulatory authority if required. The integration of ICH Good Clinical Practice principles into medical education, including the roles and responsibilities of IRB/IEC, investigators, and sponsors, is essential for building clinical trial capabilities (Integrating ICH GCP Principles into Residency Education).

Protocol Template Outline

The following outline provides a practical structure for a clinical trial protocol. This template is adapted from common elements found in published protocols and regulatory guidance.

Title Page

• Protocol title and version number
• Study phase and indication
• Sponsor name and contact information
• Principal investigator name and affiliation
• Date of protocol and amendment history

Background and Rationale

• Disease or condition overview
• Existing treatment options and their limitations
• Scientific rationale for the study intervention
• Summary of relevant preclinical and clinical data

Objectives and Endpoints

• Primary objective and primary endpoint
• Secondary objectives and secondary endpoints
• Exploratory objectives and exploratory endpoints

Study Design

• Overall design and study schema
• Randomization method and allocation ratio
• Blinding and unblinding procedures
• Study duration and visit schedule

Eligibility Criteria

• Inclusion criteria
• Exclusion criteria
• Screening and enrollment procedures

Study Intervention

• Description of the investigational product
• Dose, route, and schedule of administration
• Preparation and storage requirements
• Concomitant medications and prohibited treatments

Study Procedures

• Screening and baseline assessments
• Treatment period assessments
• Follow-up assessments
• Early termination procedures

Safety Monitoring

• Adverse event definitions and reporting
• Serious adverse event reporting
• Data safety monitoring board
• Stopping rules

Statistical Analysis Plan

• Sample size calculation
• Analysis populations
• Primary and secondary analyses
• Handling of missing data

Ethical and Regulatory Considerations

• Informed consent process
• Confidentiality and data protection
• Protocol amendments and deviations
• Trial registration and results reporting

Quality Assurance and Monitoring

• Site monitoring plan
• Data management procedures
• Quality control measures

References

• Relevant literature and regulatory guidance

Common Failure Patterns in Protocol Development

Over-Complexity

Protocols that are over-complex are a main risk for slow enrollment and data variability (How to Make a Protocol Patient-Centric). Unnecessary visits and assessments increase the burden on participants and sites, leading to higher dropout rates and more protocol deviations. The solution is to rigorously evaluate each required visit and assessment and to eliminate those that do not contribute to the study objectives.

Ambiguous Endpoints

Endpoints that are not precisely defined can lead to inconsistent data collection and analysis. The VERITAC-2 protocol specified that progression-free survival would be assessed by blinded independent central review in the intention-to-treat population and the ESR1 mutation-positive subpopulation (VERITAC-2 Study). This level of detail ensures that all sites assess the endpoint consistently.

Inadequate Safety Monitoring

Protocols that do not adequately address safety monitoring can put participants at risk and compromise data integrity. The template protocol for vaccine trials was designed to include safety-relevant information required by regulatory authorities (Template Protocol for Vaccine Trials). This includes definitions of adverse events, reporting procedures, and stopping rules.

Poorly Defined Interventions

Interventions that are not described in sufficient detail cannot be replicated. The EFICAN trial used a consensus-based exercise reporting template to describe the intervention, including the number of sessions, the duration of each session, and the progression criteria (EFICAN Study Protocol). This approach maximizes transparency and clinical applicability.

Insufficient Statistical Planning

The statistical analysis plan must be developed in consultation with a qualified statistician. The PRIMARY2 trial planned to recruit 660 participants and used a 1:1 randomization ratio in permuted blocks stratified by center (PRIMARY2 Trial Protocol). The sample size calculation was based on pilot data and the expected effect size.

Records and Measurements

Protocol Version Control

Protocol amendments are common during the lifecycle of a trial. The analysis of 14 clinical trials found that longer study participation was associated with an increased number of protocol deviations, and that amendments triggering informed consent changes were a key risk indicator (Impact of Protocol Amendments on Study Protocol Adherence). Version control is essential to ensure that all sites are working from the most current version of the protocol.

Protocol Deviation Documentation

Protocol deviations are divided into non-important (minor) or important (major) categories, and the latter can jeopardize participant rights, safety, or the quality of data generated by the study (Practical Guidelines for Standardised Resolution of Important Protocol Deviations). Existing guidelines on protocol deviation management do not detail or standardize actions to be taken for participants, investigational products, data, or samples. The proposed guidelines address this gap and promote standardization of actions to address important protocol deviations in clinical trials.

Feasibility Metrics

Pilot trials often include feasibility metrics as secondary outcomes. The Probe-Fluid pilot trial included feasibility metrics, patient outcomes, resource use, safety outcomes, and process measures as secondary outcomes (Probe-Fluid Pilot Trial Protocol). These metrics help determine whether a larger trial is feasible and inform the design of the definitive study.

Quality and Welfare Controls

Training and Standardization

Study staff behavior can influence study outcomes. The PINgPOng study was designed to analyze the influence of a study team trained to either minimize or maximize placebo responses on the results of a randomized controlled trial (PINgPOng Study Protocol). The results of this study will help to control placebo effects through education of clinical staff.

Laboratory Quality

The World Health Organization Laboratory Quality Management System Handbook provides guidance on establishing and maintaining quality in laboratory testing (WHO Laboratory Quality Management System Handbook). The WHO Laboratory Biosafety Manual addresses the safe handling of biological materials (WHO Laboratory Biosafety Manual). These resources are relevant to clinical trials that involve laboratory testing.

Bioanalytical Method Validation

For trials that involve the measurement of drug concentrations in biological samples, the U.S. Food and Drug Administration Bioanalytical Method Validation Guidance provides recommendations for the validation of bioanalytical methods (FDA Bioanalytical Method Validation Guidance). The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides additional guidance on assay development and validation (Assay Guidance Manual).

Limitations and Professional Escalation Criteria

Limitations of Protocol Templates

Protocol templates are useful starting points, but they must be adapted to the specific study. The template protocol for vaccine trials was intended as a guide for phases I through IV clinical trials and may be helpful for future site strengthening efforts (Template Protocol for Vaccine Trials). Templates should not be used without careful review by the research team.

When to Escalate to a Specialist

Certain protocol elements require specialized expertise. The statistical analysis plan should be reviewed by a qualified biostatistician. The safety monitoring plan should be reviewed by a clinician with experience in the therapeutic area. The bioanalytical method validation should be reviewed by a laboratory scientist with expertise in the relevant analytical techniques.

When to Seek Regulatory Advice

If there is uncertainty about regulatory requirements, the sponsor should seek advice from the relevant regulatory authority. The integration of ICH GCP principles into medical education emphasizes the roles and responsibilities of IRB/IEC, investigators, and sponsors (Integrating ICH GCP Principles into Residency Education). Regulatory authorities can provide guidance on the specific requirements for the study.

Safety and Regulatory Context

Good Clinical Practice

Clinical trials should be conducted according to the principles of ICH GCP and the Declaration of Helsinki. The PINgPOng study was conducted according to these principles on the Phase I Unit of the University Hospital Bonn (PINgPOng Study Protocol). ICH GCP provides international standards for the design, conduct, recording, and reporting of clinical trials.

Trial Registration

Clinical trials should be registered in a public registry before enrollment begins. The VERITAC-2 study was registered on ClinicalTrials.gov as NCT05654623 (VERITAC-2 Study). The PRIMARY2 trial was registered on ClinicalTrials.gov as NCT05154162 (PRIMARY2 Trial Protocol). Registration promotes transparency and reduces the risk of selective reporting.

Informed Consent

The informed consent process must be described in the protocol. The ProPAC-COVID protocol specified that informed consent must be signed by the patient (ProPAC-COVID Protocol). The consent form should be written in language that is understandable to the participant and should describe the purpose of the study, the procedures involved, the risks and benefits, and the participant's rights.

Frequently Asked Questions

What is the difference between a protocol and a protocol amendment?

A protocol is the original document that describes the study design and procedures. A protocol amendment is a formal change to the approved protocol. Amendments may be required to address new safety information, to modify eligibility criteria, or to correct errors. The analysis of 14 clinical trials found that amendments triggering informed consent changes were a key risk indicator for protocol deviations (Impact of Protocol Amendments on Study Protocol Adherence).

How long should a clinical trial protocol be?

There is no fixed length for a clinical trial protocol. The length depends on the complexity of the study, the number of endpoints, and the level of detail required. The SPIRIT 2025 statement identifies the minimum items that should be addressed in a protocol, but does not specify a page limit (SPIRIT 2025 Statement). The goal is to provide sufficient detail for the study to be conducted and reported without being over-complex.

What is the role of the statistical analysis plan in a protocol?

The statistical analysis plan describes how the data will be analyzed, including the sample size calculation, the primary and secondary analyses, and the methods for handling missing data. The PRIMARY2 trial planned to recruit 660 participants and used a 1:1 randomization ratio in permuted blocks stratified by center (PRIMARY2 Trial Protocol). The statistical analysis plan should be developed in consultation with a qualified biostatistician.

How can patient input improve a clinical trial protocol?

Patient input can improve the feasibility and acceptability of a study by identifying unnecessary visits and assessments and by highlighting potential barriers to participation. The RECOVER Clinical Trials Protocol Working Groups found that patient representatives contributed valuable perspectives on participant burden and lived experience (Engaging Patients in RECOVER Protocol Development). Structured engagement practices and clear expectations are necessary to ensure meaningful participation.

What are the most common causes of protocol deviations?

Protocol deviations can result from unclear instructions, complex procedures, and inadequate training. A retrospective analysis of 14 clinical trials found that longer study participation was associated with an increased number of protocol deviations (Impact of Protocol Amendments on Study Protocol Adherence). Site preparedness and patient compliance can mitigate these risks.

How should important protocol deviations be managed?

Important protocol deviations can jeopardize participant rights, safety, or the quality of data generated by the study (Practical Guidelines for Standardised Resolution of Important Protocol Deviations). The proposed guidelines for standardizing the resolution of important protocol deviations advise actions that complement existing local institutional review board and national regulatory authority requirements.

What is the role of a data safety monitoring board?

A data safety monitoring board is an independent committee that reviews safety data during the course of a trial. The protocol should describe the composition of the board, the frequency of reviews, and the stopping rules. The template protocol for vaccine trials was designed to include safety-relevant information required by regulatory authorities (Template Protocol for Vaccine Trials).

How does the SPIRIT 2025 statement differ from the 2013 version?

The SPIRIT 2025 statement updated the recommendations for minimum items to address in the protocol of a randomized trial. The update added 2 new protocol items, revised 5 items, and deleted or merged 5 items (SPIRIT 2025 Statement). Notable changes include a new open-science section, additional emphasis on the assessment of harms and description of interventions and comparators, and a new item on how patients and the public will be involved in trial design, conduct, and reporting.

Related Articles

• Aseptic Technique in Microbiology Lab: Essential Steps and Best Practices
• How to Prepare PCR Master Mix: Components, Ratios, and Best Practices
• RNA Extraction Using TRIzol Reagent: Protocol, Troubleshooting, and Best Practices
• Drop Plate Method for Viable Cell Counting: Protocol and Best Practices
• qPCR Data Normalization: Methods and Best Practices

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.. Future oncology (London, England), 2024.
• SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomized Trials.. JAMA, 2025.
• Effects of a 12-week resistance and aerobic exercise program on muscular strength and quality of life in breast cancer survivors: Study protocol for the EFICAN randomized controlled trial.. Medicine, 2019.
• Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [(68)Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.. European urology oncology, 2024.
• Proactive Prescription-Based Fluid Management Versus Usual Care in Critically Ill Patients on Kidney Replacement Therapy (Probe-Fluid): A Pilot Clinical Trial Protocol.. Canadian journal of kidney health and disease, 2025.
• Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.. BJU international, 2020.
• The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorder.. European archives of psychiatry and clinical neuroscience, 2026.
• Template protocol for clinical trials investigating vaccines--focus on safety elements.. Vaccine, 2013.
• Oral health reception and risk classification protocol: development and validation in a dental emergency service.. 2026.
• Engaging patients and researchers in RECOVER clinical trial protocol development: Key lessons.. 2026.
• PURSUIT Protocol: Development of a Novel Approach to Managing Youth Physical and Mental Health in Schools. 2026.
• Outdoor bicycle training following stroke: protocol development, feasibility testing and application guidelines.. 2026.
• PURSUIT Protocol: Development of a Novel Approach to Managing Youth Physical and Mental Health in Schools.. 2026.
• Integrating ICH Good Clinical Practice (GCP) Principles and Essential Documentation into Dermatology Residency Education in China. Advances in Medical Education and Practice, 2025.
• Impact of Protocol Amendments, Personnel Experience and Social Determinants of Health on Study Protocol Adherence in Clinical Trials with Combination Products. Therapeutic Innovation and Regulatory Science, 2025.
• Practical Guidelines for Standardised Resolution of Important Protocol Deviations in Clinical Trials Conducted in Sub-Saharan Africa. Therapeutic Innovation and Regulatory Science, 2024.
• Influence on study outcomes of an inpatient study by the behavior of the study staff (PINgPOng): study protocol for a randomized clinical trial. Trials, 2022.
• How to make a protocol patient-centric?. 2021.
• Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020.
• TYPICAL ERRORS IN SELECTING CRITICAL CHARACTERISTICS OF THE CLINICAL TRIAL PROTOCOL FOR ASSESSING THE DRUG EFFICACY. Eksperimental Naya I Klinicheskaya Farmakologiya, 2024.
• Elements of Clinical Trial Protocol Design. Quintessence of Basic and Clinical Research and Scientific Publishing, 2023.
• Attempt to develop Japanese translation of "NIH and FDA release protocol template for phase 2 and 3 IND/IDE clinical trials". Japanese Journal of Clinical Pharmacology and Therapeutics, 2018.
• Physiotherapeutic interventions in the immediate postpartum period after cesarean section for prevention and relief of pain: study protocol for a randomized clinical trial. Trials, 2026.
• TENS alone or combined with low-level laser therapy photobiomodulation for pain, functional capacity, and cardiorespiratory physiological variables after cesarean section: protocol for a randomized clinical trial. Plos One, 2025.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.